Accendra Health, Inc. filed a Form 8-K on November 18, 2026, disclosing that NYSE Regulation suspended trading in its common stock on November 16, 2026, and commenced proceedings to delist the shares.

Key Highlights

  • Trading suspended: NYSE Regulation notified Accendra Health on November 16, 2026, that it had suspended trading of the company's common stock.
  • Delisting basis: NYSE Regulation determined the common stock is "no longer suitable for listing based on abnormally low selling price levels," citing Section 802.01D of the NYSE Listed Company Manual.
  • No appeal planned: According to the filing, the company does not intend to appeal the NYSE's determination.
  • OTCQB trading begins: The company's common stock began trading on the OTCQB market under the ticker symbol "ACCH" on November 17, 2026.
  • SEC application pending: The NYSE Notice states it will apply to the U.S. Securities and Exchange Commission to delist the common stock pending completion of applicable procedures.

NYSE Suspends Accendra Health Common Stock Over Abnormally Low Price

Accendra Health, Inc. (NYSE:ACH), a Virginia-incorporated company headquartered at 4435 Waterfront Drive, Suite 300, Glen Allen, Virginia, disclosed in a Form 8-K filed November 18, 2026, that it received a notice from NYSE Regulation on November 16, 2026, suspending trading of its common stock and commencing delisting proceedings. The filing states that NYSE Regulation determined the stock is no longer suitable for listing "based on abnormally low selling price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual."

According to the filing, the company retains the right to request a review of the determination by a Committee of the Board of Directors of the Exchange. However, the company disclosed that it "does not intend to appeal the NYSE's determination." The filing further states that NYSE will apply to the U.S. Securities and Exchange Commission to delist the common stock, pending completion of applicable procedures, including any appeal.

Following the suspension, the filing reports that the company's common stock began trading on the OTCQB market under the ticker symbol "ACCH" on November 17, 2026. The filing also notes that on November 17, 2026, the company issued a press release regarding the delisting determination, furnished as Exhibit 99.1 to the Form 8-K. The report was signed by Jonathan A. Leon, Executive Vice President and Chief Financial Officer, on November 17, 2026.

What Was Disclosed

Accendra Health filed an 8-K reporting that NYSE Regulation suspended trading of its common stock and initiated delisting proceedings on November 16, 2026, citing abnormally low selling price levels. The company stated it will not appeal, and its shares moved to the OTCQB market under "ACCH."